[go: up one dir, main page]

BR9911861A - Inibidores de farnesil proteìna transferase com as propriedades radiossensibilizadoras in vivo - Google Patents

Inibidores de farnesil proteìna transferase com as propriedades radiossensibilizadoras in vivo

Info

Publication number
BR9911861A
BR9911861A BR9911861-0A BR9911861A BR9911861A BR 9911861 A BR9911861 A BR 9911861A BR 9911861 A BR9911861 A BR 9911861A BR 9911861 A BR9911861 A BR 9911861A
Authority
BR
Brazil
Prior art keywords
vivo
protein transferase
transferase inhibitors
farnesyl protein
radiosensitizing properties
Prior art date
Application number
BR9911861-0A
Other languages
English (en)
Inventor
Robert Franciscus Van Ginckel
Win Joanna Floren
David William End
Walter Boudewijn Leopo Wouters
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR9911861A publication Critical patent/BR9911861A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Patente de Invenção: <B>"INIBIDORES DE FARNESIL PROTEìNA TRANSFERASE COM AS PROPRIEDADES RADIOSSENSIBILIZADORAS IN VIVO"<D>. A presente invenção refere-se à descoberta de que os inibidores de farnesil proteína transferase têm propriedades radiossensibilizadoras o que os torna úteis para a preparação de uma composição farmacêutica para administração antes, durante ou após a irradiação de um tumor para tratamento de câncer in vivo.
BR9911861-0A 1998-07-06 1999-06-30 Inibidores de farnesil proteìna transferase com as propriedades radiossensibilizadoras in vivo BR9911861A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98202257 1998-07-06
EP98204330 1998-12-18
PCT/EP1999/004545 WO2000001411A1 (en) 1998-07-06 1999-06-30 Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties

Publications (1)

Publication Number Publication Date
BR9911861A true BR9911861A (pt) 2001-03-20

Family

ID=26150503

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9911861-0A BR9911861A (pt) 1998-07-06 1999-06-30 Inibidores de farnesil proteìna transferase com as propriedades radiossensibilizadoras in vivo

Country Status (31)

Country Link
US (1) US6545020B1 (pt)
EP (1) EP1094839B1 (pt)
JP (1) JP4530537B2 (pt)
KR (1) KR100591603B1 (pt)
CN (1) CN1152716C (pt)
AP (1) AP1599A (pt)
AT (1) ATE238811T1 (pt)
AU (1) AU762423B2 (pt)
BG (1) BG64941B1 (pt)
BR (1) BR9911861A (pt)
CA (1) CA2336624C (pt)
CZ (1) CZ300968B6 (pt)
DE (1) DE69907461T2 (pt)
DK (1) DK1094839T3 (pt)
EA (1) EA003877B1 (pt)
EE (1) EE04582B1 (pt)
ES (1) ES2199579T3 (pt)
HK (1) HK1034451A1 (pt)
HR (1) HRP20000903A2 (pt)
HU (1) HU229076B1 (pt)
ID (1) ID26987A (pt)
IL (2) IL140721A0 (pt)
MY (1) MY126519A (pt)
NO (1) NO328178B1 (pt)
PL (1) PL193464B1 (pt)
PT (1) PT1094839E (pt)
SI (1) SI1094839T1 (pt)
SK (1) SK284723B6 (pt)
TR (1) TR200003879T2 (pt)
TW (1) TW586937B (pt)
WO (1) WO2000001411A1 (pt)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP1597A (en) 1998-07-06 2006-04-26 Janssen Pharmaceutica Nv Farnesyl protein transferase inhibitors for treating arthropathies.
ES2199579T3 (es) 1998-07-06 2004-02-16 Janssen Pharmaceutica N.V. Inhibidores de la proteina farnesil-transferasa con propiedades de sensibilizacion in vivo.
WO2001056552A2 (en) * 2000-02-04 2001-08-09 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitors for treating breast cancer
JO2361B1 (en) 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
EP1322636A1 (en) 2000-09-25 2003-07-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6- (substituted phenyl)methyl]-quinoline and quinazoline derivatives
EP1322650B1 (en) 2000-09-25 2008-09-24 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
EP1322635B1 (en) 2000-09-25 2006-03-22 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
EP1322644A1 (en) 2000-09-25 2003-07-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
WO2002042296A1 (en) 2000-11-21 2002-05-30 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting benzoheterocyclic derivatives
EP1347966B1 (en) 2000-12-27 2006-03-08 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives
ES2263684T3 (es) * 2000-12-27 2006-12-16 Janssen Pharmaceutica N.V. Derivados de 4-heterociclil-quinolina y -quinazolina que inhiben la farnesil transferasa.
WO2003000266A1 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel quinolines and uses thereof
US7408063B2 (en) 2001-12-19 2008-08-05 Janssen Pharmaceutica, N.V. 1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors
CA2478813C (en) 2002-03-22 2011-10-18 Janssen Pharmaceutica N.V. Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors
WO2003087101A1 (en) 2002-04-15 2003-10-23 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles
WO2005054201A1 (en) * 2003-11-20 2005-06-16 Janssen Pharmaceutica N.V. 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
JP4691041B2 (ja) 2003-11-20 2011-06-01 チルドレンズ ホスピタル メディカル センター Ｇｔｐアーゼ阻害剤および使用方法
EP1744751A4 (en) * 2004-03-18 2010-03-10 Brigham & Womens Hospital TREATMENT OF SYNUCLEINOPATHIES
WO2005089515A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
WO2005089518A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Uch-l1 expression and cancer therapy
US20050288298A1 (en) * 2004-03-18 2005-12-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
WO2005089504A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
JP2009508809A (ja) 2005-07-29 2009-03-05 チルドレンズ ホスピタル メディカル センター ＲＡＣ−１ＧＴＰａｓｅのＧＴＰａｓｅ阻害因子とその使用方法およびその結晶構造
CA2634598A1 (en) 2005-12-23 2007-07-05 Link Medicine Corporation Treatment of synucleinopathies
DK2160386T3 (da) * 2007-05-23 2012-08-27 Allergan Inc Terapeutiske ((phenyl)imidazolyl)methylquinolinylforbindelser
US8232402B2 (en) * 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
EP2138844B1 (en) 2008-06-26 2012-04-25 SpheroTec GmbH Method for testing the response of cells to exposures with therapeutics
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US8343996B2 (en) * 2008-11-13 2013-01-01 Astrazeneca Ab Azaquinolinone derivatives and uses thereof
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
WO2013166043A1 (en) 2012-05-02 2013-11-07 Children's Hospital Medical Center Rejuvenation of precursor cells
AU2013331493A1 (en) 2012-10-16 2015-04-09 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORyt
CN105073729A (zh) 2012-10-16 2015-11-18 詹森药业有限公司 RORγt的苯基连接的喹啉基调节剂
SI2909192T1 (sl) 2012-10-16 2017-08-31 Janssen Pharmaceutica Nv Metilensko vezani kinolinilni modulatorji za ROR-gama-t
AU2014334619A1 (en) 2013-10-15 2016-04-21 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORyt
ES2742843T3 (es) 2013-10-15 2020-02-17 Janssen Pharmaceutica Nv Moduladores de quinolinilo de ROR(gamma)t
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US10028503B2 (en) 2014-06-18 2018-07-24 Children's Hospital Medical Center Platelet storage methods and compositions for same
ES2741782T3 (es) 2015-08-17 2020-02-12 Kura Oncology Inc Métodos para tratar pacientes con cáncer a partir de inhibidores de la farnesiltransferasa
US20190119758A1 (en) 2016-04-22 2019-04-25 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
EA201991091A1 (ru) 2016-11-03 2019-11-29 Способы лечения пациентов со злокачественными новообразованиями с применением ингибиторов фарнезилтрансферазы
US9956215B1 (en) 2017-02-21 2018-05-01 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
ES2927228T3 (es) 2017-02-21 2022-11-03 Kura Oncology Inc Métodos de tratamiento del cáncer con inhibidores de farnesil transferasa
US10806730B2 (en) 2017-08-07 2020-10-20 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
MX2020001207A (es) 2017-08-07 2020-03-20 Kura Oncology Inc Metodos de tratamiento del cancer con inhibidores de farnesiltransferasa.
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
AU2019372141A1 (en) 2018-11-01 2021-05-27 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
US20220142983A1 (en) 2019-03-01 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
TW202108170A (zh) 2019-03-15 2021-03-01 美商庫拉腫瘤技術股份有限公司 以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症患者之方法
AU2020254492A1 (en) 2019-03-29 2021-11-11 Kura Oncology, Inc. Methods of treating Squamous Cell Carcinomas with farnesyltransferase inhibitors
WO2020205387A1 (en) 2019-04-01 2020-10-08 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2020223583A1 (en) 2019-05-02 2020-11-05 Kura Oncology, Inc. Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
EP4461315A3 (en) 2019-08-16 2025-03-05 Children's Hospital Medical Center Cdc-42 inhibitors for use in the treatment of age-related depression, sarcopenia or frailty

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141851A (en) * 1990-04-18 1992-08-25 Board Of Regents, The University Of Texas System Isolated farnesyl protein transferase enzyme
US6083917A (en) * 1990-04-18 2000-07-04 Board Of Regents, The University Of Texas System Methods and compositions for the identification, characterization and inhibition of farnesyltransferase
US5602184A (en) * 1993-03-03 1997-02-11 The United States Of America As Represented By Department Of Health And Human Services Monoterpenes, sesquiterpenes and diterpenes as cancer therapy
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
SI0865440T1 (en) * 1995-12-08 2002-08-31 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives
WO1997038697A1 (en) * 1996-04-15 1997-10-23 The Trustees Of The University Of Pennsylvania Sensitization of cells to radiation and chemotherapy
AU709409B2 (en) * 1996-07-15 1999-08-26 Bristol-Myers Squibb Company Thiadioxobenzodiazepine inhibitors of farnesyl protein transferase
TW591030B (en) 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
ES2199579T3 (es) 1998-07-06 2004-02-16 Janssen Pharmaceutica N.V. Inhibidores de la proteina farnesil-transferasa con propiedades de sensibilizacion in vivo.
ID29584A (id) * 1999-02-11 2001-09-06 Pfizer Prod Inc Turunan-turunan kuinolin-2-on tersubstitusi heteroaril yang bermanfaat sebagai zat-zat anti kanker

Also Published As

Publication number Publication date
SI1094839T1 (en) 2003-12-31
EA200100111A1 (ru) 2001-06-25
CZ300968B6 (cs) 2009-09-30
BG105108A (en) 2001-11-30
PL347979A1 (en) 2002-05-06
TR200003879T2 (tr) 2007-01-22
PT1094839E (pt) 2003-09-30
TW586937B (en) 2004-05-11
HU229076B1 (en) 2013-07-29
HK1034451A1 (en) 2001-10-26
CA2336624C (en) 2008-10-21
HUP0103689A3 (en) 2003-01-28
AU762423B2 (en) 2003-06-26
EP1094839A1 (en) 2001-05-02
ATE238811T1 (de) 2003-05-15
BG64941B1 (bg) 2006-10-31
KR100591603B1 (ko) 2006-06-20
NO20010082L (no) 2001-01-05
IL140721A (en) 2008-11-26
EP1094839B1 (en) 2003-05-02
HUP0103689A2 (hu) 2002-02-28
EE04582B1 (et) 2006-02-15
AP1599A (en) 2006-04-27
HRP20000903A2 (en) 2001-12-31
KR20010052770A (ko) 2001-06-25
MY126519A (en) 2006-10-31
ES2199579T3 (es) 2004-02-16
SK284723B6 (sk) 2005-10-06
JP4530537B2 (ja) 2010-08-25
DE69907461D1 (de) 2003-06-05
IL140721A0 (en) 2002-02-10
NO328178B1 (no) 2009-12-28
AU4780599A (en) 2000-01-24
JP2002519389A (ja) 2002-07-02
US6545020B1 (en) 2003-04-08
DK1094839T3 (da) 2003-08-18
EA003877B1 (ru) 2003-10-30
ID26987A (id) 2001-02-22
CN1311692A (zh) 2001-09-05
CN1152716C (zh) 2004-06-09
WO2000001411A1 (en) 2000-01-13
DE69907461T2 (de) 2004-02-19
PL193464B1 (pl) 2007-02-28
EE200000794A (et) 2002-06-17
NO20010082D0 (no) 2001-01-05
AP2001002057A0 (en) 2001-03-31
CA2336624A1 (en) 2000-01-13
SK19862000A3 (sk) 2001-12-03
CZ20004777A3 (en) 2001-05-16

Similar Documents

Publication Publication Date Title
BR9911861A (pt) Inibidores de farnesil proteìna transferase com as propriedades radiossensibilizadoras in vivo
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
BR0209147A (pt) Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais
BR9807824A (pt) Derivados de n-hidróxi-beta-sulfonil-propionamida e seu uso como inibidores de metaloproteinases de matriz
BR0000003A (pt) Azalidas e métodos de preparação das mesmas
BR0109704A (pt) Método de tratamento usando conjugados de imunógeno ligando
BR9815442A (pt) Liberação terapêutica dirigida de compostos de vitamina d
MA27093A1 (fr) Derives de sulfonamides, leur preparation et leur application comme medicaments.
BR0009670A (pt) Métodos de induzir morte de células de câncer e regressão de tumor
BRPI0411155A (pt) composto que se liga a e ativa o receptor de eritropoietina, composição farmacêutica e seu uso
CY1105477T1 (el) Αναστολεις τρανσφepασης φαρνεσυλ πρωτεϊνης για τη θepαπευτικη αντιμετωπιση του καρκινου του μαστου
BR0208373A (pt) Inibidores da tirosina cinase
AR023423A1 (es) Derivados de adamantano, procedimientos para su preparacion, composicion farmaceutica, procedimiento para la preparacion de la composicion farmaceutica, yuso de dichos derivados para la manufactura de medicamentos
BR9915210A (pt) N-aril-amidas de ácido antranìlico-e ácido tioantranìlico
MXPA03006771A (es) Anticuerpos modificados y metodos de uso.
BRPI0406883A (pt) Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
BR0207487A (pt) Método de tratamento de tumores em mamìferos e uso de compostos de epotilona
BR9916422A (pt) Saponinas antiprotozoárias
MEP20908A (en) Thienopyrazoles
BR0209128A (pt) Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
BR0009608A (pt) Compostos para imunoterapia e diagnóstico de câncer de mama e métodos para sua utilização
PT1268472E (pt) Inibidores 3-aminopirazolicos de cinases dependentes da ciclina
BR0107262C1 (pt) Composição a base de monoterpenos, com efeito, quimiopreventivo e quimioterápico em neoplasias malignas de seres humanos e animais, utilização dos monoterpenos na inbição do crescimento de células tumorais e no controle de metástases de tumores primários e método especìfico de utilização da composição, com efeito, quimiopreventivo e quimioterápico em seres humanos e animais
ATE415965T1 (de) Verwendung von verzweigtkettigen fettsäuren und ihrer derivate zur schmerzbehandlung
BRPI0418223A (pt) composição que compreende um extrato aquoso de folhas de vinha vermelha e um agente de melhoria da circulação sangüìnea para o tratamento de insuficiências venosas crÈnicas

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 13 E 25 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]